When Might Azilsartan Go Generic?
The patent exclusivity for azilsartan, the active ingredient in the blood pressure medication Edarbi, is a key factor in determining when generic versions may become available. Typically, drug patents last for 20 years from the filing date, but various extensions and legal challenges can alter this timeline. Information regarding the specific patent expiration dates and any ongoing litigation for azilsartan can be found on resources like DrugPatentWatch.com [1].
What Are the Key Patents for Azilsartan?
Azilsartan's market exclusivity is protected by a portfolio of patents. These patents cover the chemical compound itself, its formulations, and methods of its use. The strength and duration of these patents directly influence when other pharmaceutical companies can introduce their generic versions to the market [1].
How Do Patent Challenges Affect Generic Azilsartan?
Patent challenges, often initiated by generic manufacturers, can lead to early invalidation or revocation of patents. If azilsartan's patents are successfully challenged, generic versions could potentially reach the market sooner than their original expiration dates. Conversely, if patents are upheld, the exclusivity period will be maintained [1].
When Can Biosimilars and Generics Be Introduced?
The introduction of generic azilsartan is contingent upon the expiry or successful challenge of its patents. For branded drugs, this typically occurs after the primary patent protection period concludes. The availability of a generic version can significantly impact drug pricing and patient access [1].
What Other Drugs Are Similar to Azilsartan?
Azilsartan is an angiotensin II receptor blocker (ARB). Other ARBs used for treating hypertension include losartan, valsartan, olmesartan, and candesartan. These drugs share a similar mechanism of action in relaxing blood vessels to lower blood pressure, though they may differ in potency, side effect profiles, and pharmacokinetic properties [2].
How Much Does Generic Azilsartan Cost?
Once generic azilsartan becomes available, its price is expected to be substantially lower than the branded Edarbi. This price reduction is a common outcome with the introduction of generic medications, making them more affordable for patients and healthcare systems [2].
What Clinical Data Supports Azilsartan?
Clinical trials have demonstrated the efficacy of azilsartan in lowering blood pressure. Studies have compared its effectiveness to other ARBs and placebo, showing significant reductions in systolic and diastolic blood pressure. These trials form the basis for its approval by regulatory agencies [2].
What Are the Risks and Side Effects of Azilsartan?
Like all medications, azilsartan carries potential risks and side effects. Common side effects may include dizziness, fatigue, and upper respiratory tract infections. More serious, though less common, side effects can include angioedema and hyperkalemia. Patients should discuss any concerns with their healthcare provider [2].
Who Manufactures Edarbi and Potential Generic Versions?
Edarbi is manufactured by Takeda Pharmaceutical Company. As patents expire or are challenged, other pharmaceutical companies will seek approval to manufacture and market generic versions of azilsartan. The specific companies involved in producing generic azilsartan will become evident as the market opens [1, 3].
Sources:
[1] DrugPatentWatch.com
[2] National Institutes of Health. (n.d.). Azilsartan. Retrieved from https://medlineplus.gov/druginfo/meds/a610028.html
[3] Takeda Pharmaceutical Company Limited. (n.d.). Edarbi® (azilsartan medoxomil) tablets. Retrieved from https://www.takeda.com/en-us/our-products/edarbi/